ACET Adicet Bio, Inc. - Common Stock
$9.34
价格 · 八月 19, 2026
截至...的财报数据 八月 5, 2026
ACET 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$9.34
市值
—
P/E (TTM)
-0.5
每股收益 (TTM)
$-16.95
营收 (TTM)
—
股息收益率
—
ROE
—
负债/权益
—
52周区间
$0 – $10
ACET 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
—
EPS
$-16.95
2021-12-31
→
2025-12-31
自由现金流
—
2018-12-31
→
2024-12-31
利润率
—
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
ACET
同行中位数
P/E (TTM)
-0.5
2.6
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
ACET
同行中位数
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
ACET
同行中位数
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
ACET
同行中位数
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
ACET
同行中位数
ACET 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
12 位分析师
- 强烈买入 5 41.7%
- 买入 6 50.0%
- 持有 1 8.3%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
6 位分析师 · 2026-08-19
中位数
$22.50
平均值
$33.17
← 低于所有目标
$9.34
最低
$18.00
最高
$90.00
中位数目标
$22.50
+141.0%
平均目标
$33.17
+255.3%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
0.23%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-1.99 | $-2.07 | 0.08% |
| 2026年3月31日 | $-1.88 | $-3.17 | 1.3% |
| 2025年12月31日 | $-2.94 | $-2.86 | -0.08% |
| 2025年9月30日 | $-4.64 | $-4.73 | 0.09% |
| 2025年6月30日 | $-5.44 | $-4.97 | -0.47% |
| 2025年3月31日 | $-4.96 | $-5.41 | 0.45% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| ACET | — | -0.5 | — | — | — | — |
| ICCC | — | -51.2 | 4.3% | — | — | — |
| KLRS | $193M | -3.0 | — | — | -65.8% | — |
| ACRV | $76M | -1.2 | — | — | -61.0% | — |
| ATRA | $132M | 7.0 | -6.3% | 27.1% | -88.9% | — |
| SERA | — | -4.4 | 5.2% | -39417.3% | -39.0% | — |
| ELTX | — | -3.1 | — | — | — | — |
| FRMM | — | — | — | -6881.3% | -368.1% | — |
| ANVS | $94M | -2.5 | — | — | -164.0% | — |
| CYPH | $97M | 16.6 | — | — | 6.1% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 15
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $99M | $99M | $106M | $71M | $49M | $34M | $24M | $15M | $17M | |
| SG&A Expense | $23M | $28M | $27M | $26M | $22M | $23M | $9M | $8M | $2M | |
| Operating Expenses | $122M | $128M | $152M | $98M | $71M | $57M | $32M | $23M | $19M | |
| Operating Income | $-122M | $-128M | $-152M | $-73M | $-61M | $-39M | $-31M | $-15M | $-19M | |
| Interest Expense | $36.0K | $4.0K | $25.0K | $80.0K | $176.0K | $134.0K | · | · | · | |
| Interest Income | $6M | $11M | $10M | · | · | · | · | · | · | |
| Other Non-op | $-430.0K | $-217.0K | $-573.0K | $-919.0K | $-606.0K | $-953.0K | $2M | $5M | $-15M | |
| Pretax Income | $-117M | $-117M | $-143M | $-70M | $-62M | $-39M | $-28M | $-10M | $-34M | |
| Income Tax | $0 | $0 | $0 | $0 | $-125.0K | $-3M | $19.0K | $-589.0K | $0 | |
| Net Income | $-117M | $-117M | $-143M | $-70M | $-62M | $-37M | $-28M | $-9M | $-34M | |
| EPS (Basic) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | · | · | · | · | |
| EPS (Diluted) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 | · | · | · | · | |
| Shares (Basic) | 6,891,336 | 5,491,652 | 43,042,405 | 41,080,286 | 30,952,152 | 7,319,977 | 2,148,317 | 2,049,680 | · | |
| Shares (Diluted) | 6,891,336 | 5,491,652 | 43,042,405 | 41,080,286 | 30,952,152 | · | · | · | · | |
| EBITDA | · | $-128M | $-152M | $-73M | $-61M | · | $-85M | $-40M | · |
资产负债表 26
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $56M | $160M | $258M | $278M | $84M | $11M | $9M | $53M | |
| Short-term Investments | · | · | $0 | · | · | · | · | · | $0 | |
| Prepaid Expense | $2M | $4M | $3M | $3M | $5M | $6M | $2M | $1M | $792.0K | |
| Other Current Assets | $314.0K | $737.0K | $457.0K | $336.0K | $2.0K | $229.0K | $179.0K | $15.0K | $84.0K | |
| Current Assets | $161M | $180M | $162M | $261M | $282M | $100M | $64M | $110M | $55M | |
| PP&E (Net) | $17M | $23M | $27M | $29M | $15M | $3M | $2M | $321.0K | $39.0K | |
| PP&E (Gross) | $44M | $44M | $42M | $37M | $21M | $8M | $6M | $406.0K | $44.0K | |
| Accum. Depreciation | $27M | $21M | $15M | $9M | $6M | $5M | $4M | $85.0K | $5.0K | |
| Goodwill | · | · | $0 | $19M | $19M | $20M | · | · | · | |
| Intangibles | · | · | · | · | $0 | · | · | · | · | |
| Other Non-current Assets | $76.0K | $428.0K | $822.0K | $1M | $2M | $2M | $410.0K | · | · | |
| Total Assets | $192M | $220M | $207M | $331M | $339M | $154M | $82M | $110M | $55M | |
| Accounts Payable | $5M | $5M | $3M | $4M | $3M | $2M | $1M | $3M | $2M | |
| Accrued Liabilities | · | · | · | · | · | · | $5M | $3M | $4M | |
| Current Liabilities | $22M | $19M | $19M | $20M | $16M | $22M | $15M | $6M | $6M | |
| Capital Leases | $11M | $14M | $18M | $19M | $19M | $20M | · | · | · | |
| Deferred Tax | · | · | · | · | · | $125.0K | · | · | · | |
| Other Non-current Liabilities | $62.0K | $116.0K | $130.0K | $114.0K | $115.0K | · | $15.0K | $19.0K | · | |
| Total Liabilities | $33M | $34M | $37M | $38M | $36M | $44M | $28M | $6M | $6M | |
| Common Stock | $10.0K | $5.0K | $4.0K | $4.0K | $4.0K | $2.0K | $4.0K | $3.0K | $1.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | $176M | $2M | |
| Retained Earnings | $-615M | $-498M | $-381M | $-238M | $-168M | $-106M | $-70M | $-71M | $-34M | |
| AOCI | $102.0K | $16.0K | $0 | $0 | $0 | $24.0K | $23.0K | $-41.0K | · | |
| Stockholders' Equity | $159M | $187M | $170M | $292M | $303M | $110M | $-60M | $-34M | $-27M | |
| Liabilities + Equity | $192M | $220M | $207M | $331M | $339M | $154M | $82M | $110M | $55M | |
| Shares Outstanding | 9,586,770 | 5,160,545 | 43,270,386 | 42,954,820 | 39,736,914 | 39,736,914 | 2,155,578 | 28,055,344 | 5,659,089 |
现金流 12
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $6M | $6M | $6M | $3M | $2M | $1M | $1M | $1M | $5.0K | |
| Stock-based Comp | $14M | $22M | $20M | $17M | $13M | $5M | $1M | $2M | $470.0K | |
| Deferred Tax | $0 | $0 | $0 | $0 | $-125.0K | $-242.0K | · | · | · | |
| Operating Cash Flow | $-95M | $-92M | $-94M | $-45M | $-51M | $-42M | $-28M | $-18M | $-11M | |
| CapEx | $2M | $1M | $4M | $17M | $13M | $990.0K | $1M | $876.0K | $44.0K | |
| Investing Cash Flow | $2M | $-119M | $-4M | $-17M | $-3M | $115M | $-48M | $-16M | $-44.0K | |
| Stock Issued | $0 | $19M | $0 | $43M | $238M | · | · | · | · | |
| Net Stock Activity | · | $19M | $0 | $0 | $238M | · | · | · | · | |
| Financing Cash Flow | $75M | $111M | $236.0K | $42M | $243M | $303.0K | $77M | $11M | $64M | |
| Net Change in Cash | $-18M | $-100M | $-98M | $-20M | $189M | $74M | $1M | $-23M | $53M | |
| Free Cash Flow | · | $-93M | $-98M | $-62M | $-64M | · | $-74M | $-36M | · | |
| Levered FCF | · | $-94M | $-98M | $-62M | $-64M | · | · | · | · |
盈利能力 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROA | · | -54.8% | -53.0% | -20.8% | -25.2% | · | -81.2% | -45.6% | · | |
| ROE | · | -58.8% | -78.2% | -22.9% | -23.8% | · | -600.2% | -35.2% | · | |
| ROIC | · | -68.4% | -89.3% | -24.8% | -20.2% | · | -104.7% | -38.1% | · |
流动性与偿付能力 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 9.3 | 8.4 | 13.2 | 17.3 | · | 7.6 | 19.2 | · | |
| Quick Ratio | · | 2.9 | 8.3 | 13.1 | 17.0 | · | 2.8 | 1.2 | · | |
| Interest Coverage | · | -31903.8 | -6081.5 | -906.9 | -349.1 | · | · | · | · |
估值 (TTM) 8
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-117M | $-117M | $-143M | $-70M | $-62M | $-37M | $-28M | $-9M | $-34M | |
| Market Cap | · | $79M | $82M | $355M | $695M | · | $380M | $1.69B | · | |
| P/E | -0.5 | -0.0 | -0.6 | -5.3 | -8.7 | · | · | · | · | |
| P/B | · | 0.4 | 0.5 | 1.2 | 2.3 | · | 4.7 | 16.2 | · | |
| P / Tangible Book | 0.5 | 0.4 | 0.5 | 1.3 | 2.5 | 3.1 | · | · | · | |
| P / Cash Flow | · | -0.9 | -0.9 | -7.9 | -13.6 | · | -5.2 | -47.6 | · | |
| P / FCF | · | -0.8 | -0.8 | -5.8 | -10.8 | · | -5.1 | -47.2 | · | |
| Earnings Yield | -201.3% | -2217.3% | -175.1% | -19.0% | -11.4% | · | · | · | · |
损益表 15
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $18M | $17M | $25M | $23M | $28M | $23M | $23M | $26M | $26M | $24M | $25M | $26M | $28M | $27M | $25M | $17M | |
| SG&A Expense | $4M | $4M | $7M | $5M | $4M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $7M | $6M | |
| Operating Expenses | $22M | $22M | $32M | $28M | $32M | $30M | $31M | $33M | $33M | $31M | $32M | $52M | $35M | $33M | $32M | $23M | |
| Operating Income | $-22M | $-22M | $-32M | $-28M | $-32M | $-30M | $-31M | $-33M | $-33M | $-31M | $-32M | $-52M | $-35M | $-33M | $-32M | $-23M | |
| Interest Expense | $22.0K | $23.0K | $24.0K | $12.0K | $0 | $0 | $1.0K | $1.0K | $0 | $2.0K | $1.0K | $1.0K | $4.0K | $19.0K | $26.0K | $18.0K | |
| Interest Income | $1M | $1M | $2M | $1M | $1M | $2M | $2M | $3M | $3M | $3M | · | · | · | · | · | · | |
| Other Non-op | $-60.0K | $7.0K | $-131.0K | $-64.0K | $-223.0K | $-12.0K | $-51.0K | $-54.0K | $-51.0K | $-61.0K | $-101.0K | $-142.0K | $-124.0K | $-206.0K | $-462.0K | $-217.0K | |
| Pretax Income | $-21M | $-20M | $-31M | $-27M | $-31M | $-28M | $-29M | $-30M | $-30M | $-28M | $-29M | $-50M | $-32M | $-31M | $-30M | $-22M | |
| Income Tax | $143.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | |
| Net Income | $-21M | $-20M | $-31M | $-27M | $-31M | $-28M | $-29M | $-30M | $-30M | $-28M | $-29M | $-50M | $-32M | $-31M | $-30M | $-22M | |
| EPS (Basic) | $-1.99 | $-1.88 | $-16.01 | $-0.29 | $-5.48 | $-4.96 | $-20.31 | $-0.34 | $-0.33 | $-0.35 | $-0.68 | $-1.16 | $-0.75 | $-0.72 | $-0.73 | $-0.53 | |
| EPS (Diluted) | $-1.99 | $-1.88 | $-16.01 | $-0.29 | $-5.48 | $-4.96 | $-20.31 | $-0.34 | $-0.33 | $-0.35 | $-0.68 | $-1.16 | $-0.75 | $-0.72 | $-0.71 | $-0.53 | |
| Shares (Basic) | 10,745,553 | 10,744,621 | -266,352,070 | 91,086,464 | 5,692,816 | 5,691,965 | -255,058,338 | 90,846,293 | 90,632,045 | 79,071,652 | -85,850,959 | 42,980,641 | 42,957,035 | 42,955,688 | -80,460,835 | 41,642,815 | |
| Shares (Diluted) | 10,745,553 | 10,744,621 | -266,352,070 | 91,086,464 | 5,692,816 | 5,691,965 | -255,058,338 | 90,846,293 | 90,632,045 | 79,071,652 | -85,850,959 | 42,980,641 | 42,957,035 | 42,955,688 | -86,596,530 | 41,642,815 | |
| EBITDA | $-22M | $-22M | · | $-28M | $-32M | $-30M | · | $-33M | $-33M | $-31M | · | $-52M | $-35M | $-33M | · | $-23M |
资产负债表 22
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $33M | $36M | $39M | $29M | $35M | $28M | $56M | $105M | $224M | $248M | $160M | $183M | $205M | $232M | $258M | $283M | |
| Short-term Investments | · | · | · | · | · | · | · | $97M | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $3M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | |
| Other Current Assets | $441.0K | $348.0K | $320.0K | $619.0K | $690.0K | $478.0K | $737.0K | $543.0K | $409.0K | $613.0K | $457.0K | $378.0K | $489.0K | $511.0K | $336.0K | $380.0K | |
| Current Assets | $121M | $140M | $161M | $106M | $128M | $154M | $180M | $206M | $228M | $250M | $162M | $186M | $209M | $235M | $261M | $286M | |
| PP&E (Net) | $14M | $15M | $17M | $18M | $20M | $21M | $23M | $24M | $24M | $25M | $27M | $28M | $30M | $30M | $29M | $27M | |
| PP&E (Gross) | $44M | $44M | $44M | $44M | $44M | $44M | $44M | $44M | $42M | $42M | $42M | $41M | $41M | $40M | $37M | $35M | |
| Accum. Depreciation | $30M | $29M | $27M | $26M | $24M | $23M | $21M | $20M | $18M | $16M | $15M | $13M | $12M | $10M | $9M | $8M | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | · | $0 | $19M | $19M | $19M | $19M | |
| Other Non-current Assets | $80.0K | $78.0K | $76.0K | $110.0K | $225.0K | $314.0K | $428.0K | $508.0K | $593.0K | $691.0K | $822.0K | $916.0K | $1M | $1M | $1M | $1M | |
| Total Assets | $148M | $169M | $192M | $140M | $163M | $191M | $220M | $246M | $269M | $293M | $207M | $233M | $278M | $305M | $331M | $354M | |
| Accounts Payable | $4M | $3M | $5M | $4M | $3M | $4M | $5M | $2M | $2M | $3M | $3M | $4M | $3M | $3M | $4M | $5M | |
| Current Liabilities | $18M | $18M | $22M | $19M | $17M | $16M | $19M | $19M | $18M | $17M | $19M | $20M | $19M | $18M | $20M | $17M | |
| Capital Leases | $9M | $10M | $11M | $12M | $12M | $13M | $14M | $15M | $16M | $17M | $18M | $19M | $20M | $21M | $19M | $19M | |
| Other Non-current Liabilities | $0 | $0 | $62.0K | $125.0K | $116.0K | $116.0K | $116.0K | $116.0K | $116.0K | $116.0K | $130.0K | $143.0K | $130.0K | $116.0K | $114.0K | $116.0K | |
| Total Liabilities | $28M | $29M | $33M | $31M | $30M | $30M | $34M | $34M | $34M | $34M | $37M | $39M | $39M | $39M | $38M | $37M | |
| Common Stock | $1.0K | $1.0K | $10.0K | $8.0K | $8.0K | $8.0K | $5.0K | $8.0K | $8.0K | $8.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | |
| Retained Earnings | $-656M | $-635M | $-615M | $-584M | $-557M | $-526M | $-498M | $-469M | $-439M | $-409M | $-381M | $-351M | $-301M | $-269M | $-238M | $-208M | |
| AOCI | $-105.0K | $-37.0K | $102.0K | $56.0K | $-41.0K | $-9.0K | $16.0K | $121.0K | · | · | $0 | · | $0 | $0 | · | $0 | |
| Stockholders' Equity | $120M | $140M | $159M | $109M | $133M | $161M | $187M | $212M | $235M | $259M | $170M | $195M | $239M | $266M | $292M | $318M | |
| Liabilities + Equity | $148M | $169M | $192M | $140M | $163M | $191M | $220M | $246M | $269M | $293M | $207M | $233M | $278M | $305M | $331M | $354M | |
| Shares Outstanding | 9,361,371 | 9,597,693 | 9,586,770 | 83,253,779 | 83,252,520 | 82,709,625 | 5,160,545 | 82,400,960 | 82,400,960 | 82,169,503 | 43,270,386 | 43,107,921 | 43,066,158 | 42,957,431 | 42,954,820 | 42,787,657 |
现金流 11
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $800.0K | |
| Stock-based Comp | $1M | $1M | $6M | $2M | $3M | $3M | $4M | $7M | $6M | $6M | $5M | $6M | $5M | $5M | $4M | $4M | |
| Operating Cash Flow | $-20M | $-21M | $-21M | $-22M | $-27M | $-25M | $-24M | $-22M | $-23M | $-23M | $-23M | $-21M | $-25M | $-24M | $-19M | $-15M | |
| CapEx | $202.0K | $37.0K | $-10.0K | $209.0K | $47.0K | $1M | $176.0K | $401.0K | $302.0K | $239.0K | $136.0K | $906.0K | $2M | $2M | $6M | $5M | |
| Investing Cash Flow | $17M | $19M | $-45M | $17M | $33M | $-3M | $-22M | $-97M | $-302.0K | $-239.0K | $-136.0K | $-906.0K | $-2M | $-2M | $-6M | $-5M | |
| Stock Issued | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $19M | $0 | $0 | $0 | $0 | $0 | $43M | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $19M | · | · | · | · | · | · | |
| Financing Cash Flow | $58.0K | $-65.0K | $75M | $-150.0K | $267.0K | $-104.0K | $137.0K | $0 | $204.0K | $111M | $76.0K | $-59.0K | $226.0K | $-7.0K | $304.0K | $42M | |
| Net Change in Cash | $-3M | $-3M | $10M | $-6M | $7M | $-28M | $-46M | $-119M | $-24M | $88M | $-24M | $-22M | $-26M | $-26M | $-25M | $22M | |
| Free Cash Flow | · | $-22M | · | · | · | $-27M | · | · | · | $-23M | · | · | · | $-26M | · | · | |
| Levered FCF | · | $-22M | · | · | · | $-27M | · | · | · | $-23M | · | · | · | $-26M | · | · |
盈利能力 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -13.7% | -11.2% | · | -13.9% | -14.5% | -11.7% | · | -12.7% | -10.9% | -9.4% | · | -17.0% | -10.7% | -9.6% | · | -7.2% | |
| ROE | -16.9% | -13.4% | · | -16.8% | -16.9% | -13.4% | · | -15.0% | -12.6% | -10.7% | · | -19.5% | -12.2% | -10.7% | · | -8.2% | |
| ROIC | -18.7% | -15.4% | · | -25.6% | -24.3% | -18.5% | · | -15.7% | · | -11.9% | · | -26.9% | -14.6% | -12.5% | · | -7.2% |
流动性与偿付能力 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | 7.7 | · | 5.6 | 7.5 | 9.3 | · | 10.6 | 12.8 | 14.3 | · | 9.4 | 11.1 | 13.0 | · | 16.6 | |
| Quick Ratio | 1.8 | 2.0 | · | 1.5 | 2.0 | 1.7 | · | 10.4 | 12.5 | 14.2 | · | 9.3 | 10.9 | 12.8 | · | 16.4 | |
| Interest Coverage | -1013.7 | -937.8 | · | -2329.3 | · | · | · | -33153.0 | · | -15435.5 | · | -52262.0 | -8722.5 | -1753.8 | · | -1276.9 |
估值 (TTM) 8
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-100M | $-107M | · | $-117M | $-120M | $-117M | · | $-138M | $-140M | $-141M | · | $-135M | $-108M | $-71M | · | $-54M | |
| Market Cap | $81M | $65M | · | $67M | $51M | $62M | · | $119M | $100M | $193M | · | $59M | $105M | $247M | · | $608M | |
| P/E | -0.9 | -0.9 | · | -0.6 | -0.5 | -0.6 | · | -0.7 | -0.5 | -0.8 | · | -0.4 | -0.9 | -3.4 | · | -9.9 | |
| P/B | 0.7 | 0.5 | · | 0.6 | 0.4 | 0.4 | · | 0.6 | 0.4 | 0.7 | · | 0.3 | 0.4 | 0.9 | · | 1.9 | |
| P / Tangible Book | 0.7 | 0.5 | · | 0.6 | 0.4 | 0.4 | · | 0.6 | 0.4 | 0.7 | · | 0.3 | 0.5 | 1.0 | · | 2.0 | |
| P / Cash Flow | · | -3.0 | · | · | · | -2.5 | · | · | · | -8.5 | · | · | · | -10.3 | · | · | |
| P / FCF | · | -3.0 | · | · | · | -2.3 | · | · | · | -8.4 | · | · | · | -9.5 | · | · | |
| Earnings Yield | -111.6% | -109.7% | · | -158.0% | -216.4% | -176.2% | · | -151.4% | -214.0% | -126.8% | · | -230.7% | -105.4% | -29.7% | · | -10.1% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 净收入 | $-117M | $-117M | $-143M | $-70M | $-62M |
| 稀释后每股收益 (EPS) | $-16.95 | $-21.33 | $-3.31 | $-1.70 | $-2.00 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | — | 9.3 | 8.4 | 13.2 | 17.3 |
| 速动比率 | — | 2.9 | 8.3 | 13.1 | 17.0 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | — | $-93M | $-98M | $-62M | $-64M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 62 家申报者 · $55.5M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 20 (+10 与上一季度对比) | 6 (-4 与上一季度对比) | 14 (+1 与上一季度对比) | 10 (+3 与上一季度对比) | -34K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 28 位内幕人士 · 10 位高管 · 14 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Chen Schor | President & CEO | 2026年6月19日 A | 6820 | 0 | 0 | $0 |
| Brian Nicholas Harvey | Chief Financial Officer | 2026年1月24日 F | 5145 | 0 | 0 | $0 |
| Blake Aftab | Chief Scientific Officer | 2026年6月19日 A | 2981 | 0 | 0 | $0 |
| Don Healey | Chief Technology Officer | 2026年1月24日 F | 3452 | 0 | 0 | $0 |
| Julia D. Maltzman | Chief Medical Officer | 2025年1月31日 A | — | 0 | 0 | $0 |
| Francesco Galimi | SVP & Chief Medical Officer | 2024年6月5日 A | 101801 | 0 | 0 | $0 |
| Carrie Krehlik | Chief Human Resources Officer | 2021年2月12日 A | — | 0 | 0 | $0 |
| Joan Mannick | Chief Medical Officer | 2019年12月6日 A | 1404585 | 0 | 0 | $0 |
| John J Mccabe | Vice President, Finance | 2019年12月6日 A | 12867 | 0 | 0 | $0 |
| Meredith Manning | Chief Commercial Officer | 2019年2月27日 A | — | 0 | 0 | $0 |
| Katie Peng | 董事 | 2026年6月21日 A | 11800 | 0 | 0 | $0 |
| Andrew Sinclair | 董事 | 2026年6月21日 A | 17700 | 0 | 0 | $0 |
| Michael Grissinger | 董事 | 2026年6月21日 A | — | 0 | 0 | $0 |
| Jeffrey Chodakewitz | 董事 | 2026年6月21日 A | 17700 | 0 | 0 | $0 |
| Steve Dubin | 董事 | 2026年6月21日 A | 22700 | 0 | 0 | $0 |
| Aya Jakobovits | 董事 | 2024年8月21日 A | 11800 | 0 | 0 | $0 |
| Michael Kauffman | 董事 | 2024年8月21日 A | 5900 | 0 | 0 | $0 |
| GORDON CARL L | 董事 | 2024年8月21日 A | 11800 | 0 | 0 | $0 |
| Bastiano Sanna | 董事 | 2023年8月14日 A | 5900 | 0 | 0 | $0 |
| CHIMOVITS EREZ | 董事 | 2021年2月12日 A | 396657 | 0 | 0 | $0 |
| David Adam Steinberg | 董事 | 2020年6月3日 A | — | 0 | 0 | $0 |
| Paul R. Fonteyne | 董事 | 2020年6月3日 A | — | 0 | 0 | $0 |
| Jonathan Silverstein | 董事 | 2020年6月3日 A | 4830387 | 0 | 0 | $0 |
| PureTech Health LLC | 10% 所有者 | 2019年12月18日 S | 2119696 | 0 | 0 | $0 |
| Lloyd Klickstein | — | 2026年8月5日 A | 108566 | 0 | 0 | $0 |
| Stewart Abbot | — | 2021年6月11日 A | — | 0 | 0 | $0 |
| Yair Chaim Schindel | — | 2020年9月17日 A | 1104460 | 0 | 0 | $0 |
| Lynne Marie Sullivan | — | 2020年6月3日 A | — | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 7 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VI LLC, ORBIMED CAPITAL GP V LLC, OrbiMed Genesis GP LLC, ORBIMED ADVISORS ISRAEL II LTD, ORBIMED ISRAEL GP II, L.P., ORBIMED ISRAEL GP LTD., ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP ×10 申报 | 2026年4月10日 | 8.80% | 修订 | — | SEC |
| The Carlyle Group Inc., Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L.C., TC Group, L.L.C., Carlyle Investment Management L.L.C., Carlyle Genesis UK LLC, Abingworth LLP, Abingworth Bioventures 8 LP ×2 申报 | 2024年2月7日 | — | 初始申报 | — | SEC |
| Abingworth LLP, Abingworth Bioventures 8, LP ×2 申报 | 2021年3月16日 | — | 初始申报 | — | SEC |
| aMoon Growth Fund Limited Partnership (f/k/a aMoon 2 Fund Limited Partnership), aMoon Growth Fund G.P. Limited Partnership (f/k/a aMoon 2 Fund G.P. Limited Partnership), aMoon General Partner Ltd., Dr. Yair C. Schindel | 2021年2月18日 | — | 初始申报 | — | SEC |
| aMoon 2 Fund Limited Partnership, aMoon 2 Fund G.P. Limited Partnership, aMoon General Partner Ltd., Dr. Yair C. Schindel ×2 申报 | 2020年12月3日 | — | 初始申报 | — | SEC |
| Adicet Bio, Inc. | 2020年5月8日 | — | 初始申报 | 并购/出售 | SEC |
| PureTech Health LLC, PureTech Health plc ×3 申报 | 2020年5月5日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 4 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。